Evidence map›Paper›PMID 21818628›Full record

Trial reportEuropean archives of psychiatry and clinical neuroscience2012

Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study.

Y Likitjaroen, T Meindl, U Friese, M Wagner, K Buerger, H Hampel, S J Teipel

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European archives of psychiatry and clinical neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Apathy and brain alterations in Parkinson's disease: a multimodal imaging study.Annals of clinical and translational neurology · 2018
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Accelerated changes in white matter microstructure during aging: a longitudinal diffusion tensor imaging study.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014
    Article
  12. Destruction of white matter integrity in patients with mild cognitive impairment and Alzheimer disease.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2014
    Article
  13. Diffusion tensor imaging in Alzheimer's disease and affective disorders.European archives of psychiatry and clinical neuroscience · 2014
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Y LikitjaroenDepartment of Aging Science and Humanities, Interdisciplinary Faculty, University of Rostock, Rostock, Germany. yuttachai.likitjaroen@med.uni-rostock.de
T Meindl
U Friese
M Wagner
K Buerger
H Hampel
S J Teipel
Goethe University Frankfurt · DEUniversity of Rostock · DEGerman Center for Neurodegenerative Diseases · DELudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffusion tensor imaging (DTI) demonstrates decline of fractional anisotropy (FA) as a marker of fiber tract integrity in Alzheimer's disease (AD). We aimed to assess the longitudinal course of white matter microstructural changes in AD and healthy elderly control (HC) subjects and to evaluate the effects of treatment with the cholinesterase inhibitor galantamine on white matter microstructure in AD patients. We enrolled 28 AD patients and 11 healthy elderly control subjects (HC). AD patients were randomly assigned to 6-month double-blind galantamine treatment or placebo, with a 6-month open-label extension phase. DTI was performed at baseline, as well as at 6 and 12-month follow-up in AD patients. The HC subjects underwent DTI at baseline and 12-month follow-up without treatment. We measured FA in regions of interest covering the posterior cingulate and corpus callosum. At 6-month follow-up, the AD group showed significant FA decline in the left posterior cingulate. FA decline was significantly preserved in the posterior body of the corpus callosum in AD group with treatment compared to placebo. At 12-month follow-up, the AD patients showed no differences in FA decline between initial treatment and placebo groups after the 6-month open-label extension phase. A significant FA decline occurred in the left posterior cingulate across the AD and HC groups without between-group differences. DTI demonstrated FA decline in intracortically projecting fiber tracts in aging and AD over 1 year. Galantamine had limited impact on regional FA decline, which was not preserved after additional 6-month open-label treatment.

Indexed as

Alzheimer DiseaseCorpus CallosumGalantamineGyrus CinguliAgedAged, 80 and overAnisotropyBiological AvailabilityCholinesterase InhibitorsDiffusion Tensor ImagingDouble-Blind MethodFemaleHumansMaleNerve Fibers, MyelinatedNeuropsychological TestsCholinesterase InhibitorsGalantamine

Identifiers

PMID21818628
OpenAlexW1968231693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.